Liquid Biopsy Market

Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022

Report Code: MD 4456 Oct, 2019, by marketsandmarkets.com

[204 Pages Report] The global liquid biopsy market is projected to be valued at USD 715.7 million in 2017 and is expected to grow at a CAGR of 23.4% to reach to USD 2,047.9 million by 2022. Base year considered for the report is 2016 and forecast period includes 2017–2022. Some of the key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D.

Liquid Biopsy Market Circulation Biomarkers Market, by Region, 2022 (USD Billion)

By product and service, the assay kits segment is expected to grow at the highest growth rate during the forecast period.

Based on product and service, the liquid biopsy market is segmented into assay kits, instruments, and services. Among these, the assay kits segment is expected to be the fastest-growing segment in the product and services market during the forecast period. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected to drive the liquid biopsy market in the coming years.

By circulating biomarker, the circulating tumor DNA to register the highest CAGR during the forecast period

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers. The circulating tumor DNA segment is expected to be the fastest-growing segment in the circulating biomarkers market during the forecast period. An increase in CTCs in a patient’s bloodstream is associated with cancer progression, while a decrease is associated with cancer containment or remission.

By clinical application, the therapy selection segment is expected to grow at the highest growth rate during the forecast period.

The therapy selection segment is expected to witness a faster growth rate in this market, since it offers various benefits such as non-invasiveness, assess to tumor heterogeneity, real-time treatment monitoring, and detecting recurrence before significant tumor formation or metastasis are expected to drive the market for therapy selection.

By application, the non-cancer application segment is projected to grow at the highest CAGR during the forecast period

 Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.

By end user, the reference laboratories segment is expected to grow at the highest growth rate during the forecast period.

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The can be attributed to the large volume of tests being outsourced to reference laboratories from oncologists and hospitals.

Liquid Biopsy Market Circulation Biomarkers Market, by Region, 2022 (USD Billion)

Asia Pacific to witness the highest growth during the forecast period (2017–2022)

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.

Market Dynamics

Driver: Increasing prevalence of Cancer

Cancer is the second leading cause of death in the US and accounts for nearly one in every four deaths. The incidence rates of cancer remain highest in the more-developed regions; however, the mortality is relatively higher in the less-developed countries due to limited access to treatment facilities and lack of awareness regarding the benefits of early detection. Lung cancer, colorectal cancer, breast cancer, and prostate cancer account for the majority of cancer cases. Lung cancer is the leading cause of death among all cancers. Similarly, breast cancer is the second-most common type of cancer globally and is also the most common cause of cancer-related deaths in women.

Liquid biopsy holds several benefits over traditional cancer diagnostics techniques—reduced cost, early prognosis, therapy monitoring, detection of tumour heterogeneity, acquired drug resistance, and patient comfort (by eliminating the need for surgery)

Restraint: Low sensitivity and specificity

Recent technological advances have enabled the analysis of ctDNA and CTCs for almost all types of cancers. However, the desired sensitivity and specificity have yet to be achieved.  Advanced technologies such as ddPCR (droplet digital PCR) are capable of detecting cancer biomarkers with the sensitivity of ~100% only if there are four or more metastatic sites. If the number of metastatic sites ranges between one and three, the maximum sensitivity that could be achieved is 60%- 80%. Owing to the lack of desired sensitivity and specificity, physicians and laboratories cannot fully rely on liquid biopsies and have to use tissue biopsies in conjugation with liquid biopsies for diagnosing cancer. This factor is likely to restrain the growth of the market.

Opportunity: Growing interest in liquid biopsy

The growing demand for noninvasive and easy sample collection and the faster diagnosis of cancer is driving the growth of the liquid biopsy market. With huge investments and growing evidence of the uses/applications of liquid biopsy, companies are increasingly looking to move into the liquid biopsy market. the market is witnessing a surge in the number of inorganic developments such as partnerships, collaboration, agreements, mergers, and acquisitions; as many as 22 inorganic developments were recorded in this market between January and June 2017. Companies are focusing on inorganic strategies primarily to obtain access to innovative technologies of other players. Companies are also teaming up with universities and cancer institutes to gain robust R&D expertise.

Challenge: Unclear regulatory and reimbursement scenarios

The Liquid Biopsy’s market growth is plagued by several challenges. The liquid biopsies are classified as Laboratory – developed tests, (LDT). The US FDA recently proposed a draft to increase regulations on LDTs; however, till date, the LDT regulation remains unclear. Increased regulations on LDTs by the FDA could dramatically slow the growth of the molecular diagnostics industry as well as liquid biopsy technologies. This is also likely to increase the costs associated with introducing new tests and delay their introduction in the market.

Besides regulatory challenges, reimbursement challenges also exist in the liquid biopsy market

Liquid Biopsy Market Circulation Biomarkers Market, by Region, 2022 (USD Billion)

Scope of the Report

Report Metric

Details

Market size available for years

2015–2022

Base year considered

2016

Forecast period

2015–2022

Forecast units

Million (USD)

Segments covered

Cancer Type (Lung, Breast,Colorectal prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell Free DNA), By Product (Instruments, Assay Kits), End User (Reference Laboratory)

Geographies covered

North America, Europe, APAC, and Rest of the World (ROW)

Companies covered

QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDxHealth SA (US).

The research report categorizes the liquid biopsy market into the following segments and subsegments:

Liquid biopsy Market, by Product

  • Assays Kits
  • Instruments
  • Services

Liquid biopsy Market, by Circulating Biomarker

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers*

*Other circulating biomarkers include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers.

Liquid biopsy Market, by Clinical Application

    • Early Cancer Screening
    • Therapy Selection
    • Treatment Monitoring
    • Recurrence Monitoring Orthopedics

Liquid biopsy Market, by Application

  • Oncology
    • Lung Cancer
    • Breast Cancer 
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma Cancer
    • Other Cancers
  • Non-Cancer Application

Liquid biopsy Market, by End User

  • Reference Laboratories 
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Users

Liquid biopsy Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific (RoAPAC)
  • RoW

Key Market Players

Some of the major market players in the liquid biopsy market are

  • QIAGEN N.V. (Netherlands)

https://www.qiagen.com/us/

  • Roche Diagnostics (Switzerland)

https://www.roche.com/about/business/diagnostics.htm

  • Bio-Rad Laboratories Inc. (US)

https://www.bio-rad.com/

  • Myriad Genetics, Inc. (US)

https://myriad.com/

  • Menarini Silicon Biosystems (Italy)

https://www.siliconbiosystems.com/

Recent Developments

  • In March 2017, QIAGEN N.V. (Netherlands) launched AdhaTest Prostate Cancer Panel AR-V7. AdnaTest Prostate Cancer Panel AR-V7 A are used to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer.
  • In March 2017, Roche Diagnostics (Switzerland), launched AVENIO circulating tumor DNA (ctDNA) Analysis Kits. The kits include all reagents, bioinformatics and software to make ctDNA testing accessible to all NGS laboratories.
  • In April 2017, Myriad Genetics Inc. (US), partnered with BeiGene (Cayman Islands). BeiGene is a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. As per this partnership, BeiGene will use Myriad’s myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the clinical development of its novel PARP inhibitor, BGB-290.
  • In April 2017, Menarini Silicon Biosystems (Italy), Inc. acquired Janssen Diagnostics, LLC. (US). This acquisition of Janssen Diagnostics' business related to CELLSEARCH Circulating Tumor Cell System. The acquisition marks Menarini-Silicon Biosystems’ first entry into the US diagnostics market.

Critical questions the report answers

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the liquid biopsy market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology
    2.1 Research Approach
           2.1.1 Secondary Data
                    2.1.1.1 Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Primary Sources
                    2.1.2.2 Key Industry Insights
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Assumptions for the Study

3 Executive Summary

4 Premium Insights
    4.1 Liquid Biopsy: Market Overview
    4.2 Liquid Biopsy Market, By Clinical Application (2017)
    4.3 Liquid Biopsy Market: Geographic Growth Opportunities
    4.4 Liquid Biopsy Market: Geographic Mix
    4.5 Liquid Biopsy Market: Established vs. Emerging Markets

5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Prevalence of Cancer
                    5.2.1.2 Increasing Preference for Noninvasive Procedures
                    5.2.1.3 Initiatives Undertaken By Government and Global Health Organizations
                    5.2.1.4 Technological Advancement to Augment Market Revenues
                    5.2.1.5 Rising Emphasis on Personalized Medicine
                    5.2.1.6 Availability of Funding for Liquid Biopsy R&D
           5.2.2 Restraints
                    5.2.2.1 Low Sensitivity and Specificity
           5.2.3 Opportunities
                    5.2.3.1 Growing Interest in Liquid Biopsy
           5.2.4 Challenges
                    5.2.4.1 Unclear Regulatory and Reimbursement Scenario

6 Liquid Biopsy Market, By Product and Service
    6.1 Introduction
    6.2 Assay Kits
    6.3 Instruments
    6.4 Services

7 Liquid Biopsy Market, By Circulating Biomarker
    7.1 Introduction
    7.2 Circulating Tumor Cells
    7.3 Circulating Tumor Dna (Ctdna)
    7.4 Cell-Free Dna
    7.5 Extracellular Vesicles (EVS)
    7.6 Other Circulating Biomarkers

8 Liquid Biopsy Market, By Clinical Application
    8.1 Introduction
    8.2 Early Cancer Screening
    8.3 Therapy Selection
    8.4 Treatment Monitoring
    8.5 Recurrence Monitoring

9 Liquid Biopsy Market, By Technology
    9.1 Introduction
    9.2 Multi-Gene-Parallel Analysis Using Ngs
    9.3 Single Gene Analysis Using Pcr Microarrays

10 Liquid Biopsy Market, By Application
     10.1 Introduction
     10.2 Cancer Applications
             10.2.1 Low Sensitivity and Specificity
             10.2.2 Opportunities
             10.2.3 Growing Interest in Liquid Biopsy
             10.2.4 Challenges
             10.2.5 Unclear Regulatory and Reimbursement Scenario
             10.2.6 Liquid Biopsy Market, By Product and Service
     10.3 Non-Cancer Applications

11 Liquid Biopsy Market, By End User
     11.1 Introduction
     11.2 Reference Laboratories
     11.3 Hospitals and Physician Laboratories
     11.4 Academic and Research Centers
     11.5 Other End Users

12 Liquid Biopsy Market, By Region
     12.1 Introduction
     12.2 North America
             12.2.1 Other Circulating Biomarkers
             12.2.2 Liquid Biopsy Market, By Clinical Application
     12.3 Europe
             12.3.1 Early Cancer Screening
             12.3.2 Therapy Selection
             12.3.3 Treatment Monitoring
             12.3.4 Recurrence Monitoring
     12.4 Asia Pacific
             12.4.1 Introduction
             12.4.2 Multi-Gene-Parallel Analysis Using Ngs
             12.4.3 Single Gene Analysis Using Pcr Microarrays
             12.4.4 Liquid Biopsy Market, By Application
     12.5 Rest of the World (RoW)

13 Competitive Landscape
     13.1 Introduction
     13.2 Market Ranking Analysis
     13.3 Competitive Leadership Mapping
             13.3.1 Prostate Cancer
             13.3.2 Melanoma
             13.3.3 Other Cancers
             13.3.4 Non-Cancer Applications

14 Competitive Benchmarking
     14.1 Introduction
     14.2 Reference Laboratories

15 Company Profiles
(Business Overview, Products Offered, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments)* 
     15.1 Biocept, Inc
             15.1.1 Liquid Biopsy Market, By Region
             15.1.2 Introduction
             15.1.3 North America
             15.1.4 US
             15.1.4 Canada
     15.2 Qiagen N.V.
             15.2.1 Germany
             15.2.2 France
             15.2.3 UK
             15.2.4 Rest of Europe
             15.2.4 Asia Pacific
     15.3 Roche Diagnostics
             15.2.1 China
             15.3.2 India
             15.3.3 Rest of Asia Pacific
             15.3.4 Rest of the World (RoW)
             15.3.4 Competitive Landscape
     15.4 Bio-Rad Laboratories, Inc.
             15.4.1 Market Ranking Analysis
             15.4.2 Competitive Leadership Mapping
             15.4.3 Visionary Leaders
             15.4.4 Innovators
             15.4.4 Dynamic Differentiators
     15.5 Myriad Genetics, Inc
             15.5.1 Competitive Benchmarking
             15.5.2 Strength of Product Portfolio (25 Companies)
             15.5.3 Business Strategy Excellence (25 Companies)
             15.5.4 Company Profiles
             15.5.4
     15.6 Menarini-Silicon Biosystems
             15.6.1 Business Overview
             15.6.2 Products Offered
             15.6.3 Strength of Product Portfolio
             15.6.4 Business Strategy Excellence
             15.6.4 Recent Developments
     15.7 Trovagene, Inc.
             15.7.1 Business Overview
             15.7.2 Products Offered
             15.7.3 Strength of Product Portfolio
             15.7.4 Business Strategy Excellence
             15.7.4 Recent Developments
     15.8 Guardant Health, Inc.
             15.8.1 Business Overview
             15.8.2 Products Offered
             15.8.3 Strength of Product Portfolio
             15.8.4 Business Strategy Excellence
             15.8.4 Recent Developments
     15.9 Mdxhealth SA
             15.9.1 Business Overview
             15.9.2 Products Offered
             15.9.3 Strength of Product Portfolio
             15.9.4 Business Strategy Excellence
             15.9.4 Recent Developments
     15.10 Genomic Health, Inc.
             15.10.1 Business Overview
             15.10.2 Products Offered
             15.10.3 Strength of Product Portfolio
             15.10.4 Business Strategy Excellence
             15.10.4 Recent Developments
     15.11 Raindance Technologies, Inc
             15.11.1 Business Overview
             15.11.2 Products Offered
             15.11.3 Strength of Product Portfolio
             15.11.4 Business Strategy Excellence
             15.11.4 Recent Developments
     15.12 Thermo Fisher Scientific Inc.
             15.12.1 Business Overview
             15.12.2 Products Offered
             15.12.3 Strength of Product Portfolio
             15.12.4 Business Strategy Excellence
             15.12.4 Recent Developments
     15.13 Illumina, Inc.
             15.13.1 Business Overview
             15.13.2 Products Offered
             15.13.3 Strength of Product Portfolio
             15.13.4 Business Strategy Excellence
             15.13.4 Recent Developments
* Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments Might Not Be Captured in Case of Unlisted Companies. 

16 Appendix
     16.1 Insights of Industry Experts
     16.2 Discussion Guide
     16.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     16.4 Introducing Rt: Real-Time Market Intelligence
     16.5 Available Customizations
     16.6 Related Reports
     16.7 Author Details


List of Tables (133 Tables)

Table 1 Conferences and Awareness Programs on Liquid Biopsy
Table 2 Liquid Biopsy Products Launched in Recent Years
Table 3 Liquid Biopsy Market: Funding (2014 - 2017)
Table 4 Companies Selling/Developing Liquid Biopsy Tests for Oncology, in the Us
Table 5 Liquid Biopsy Market, By Product and Service, 2015–2022 (USD Million)
Table 6 Liquid Biopsy Market for Assay Kits, By Country, 2015–2022 (USD Million)
Table 7 Specifications: Ngs and Ddpcr for Cancer Liquid Biopsies
Table 8 Liquid Biopsy Market for Instruments, By Country, 2015–2022 (USD Million)
Table 9 Liquid Biopsy Market for Services, By Country, 2015–2022 (USD Million)
Table 10 Advantages and Limitations of Ctcs, Ctdna, and Exosomes
Table 11 Liquid Biopsy Market, By Circulating Biomarker, 2015–2022 (USD Million)
Table 12 Companies Active in the Ctcs Segment
Table 13 Liquid Biopsy Market for Circulating Tumor Cells, By Country,  2015–2022 (USD Million)
Table 14 Liquid Biopsy Market for Circulating Tumor Dna, By Country,  2015–2022 (USD Million)
Table 15 Liquid Biopsy Market for Cell-Free Dna, By Country, 2015–2022 (USD Million)
Table 16 Liquid Biopsy Market for Extracellular Vesicles, By Country,  2015–2022 (USD Million)
Table 17 Liquid Biopsy Market for Other Circulating Biomarkers, By Country,  2015–2022 (USD Million)
Table 18 Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 19 Liquid Biopsy Market for Early Cancer Screening, By Country/Region,  2015–2022 (USD Thousands)
Table 20 Liquid Biopsy Market for Therapy Selection, By Country/Region,  2015–2022 (USD Million)
Table 21 Liquid Biopsy Market for Treatment Monitoring, By Country/Region,  2015–2022 (USD Million)
Table 22 Liquid Biopsy Market for Recurrence Monitoring, By Country/Region,  2015–2022 (USD Million)
Table 23 Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 24 Liquid Biopsy Market for Cancer Applications, By Country/Region,  2015–2022 (USD Million)
Table 25 Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 26 Liquid Biopsy Market for Lung Cancer, By Country/Region,  2015–2022 (USD Million)
Table 27 Liquid Biopsy Market for Breast Cancer, By Country/Region,  2015–2022 (USD Million)
Table 28 Liquid Biopsy Market for Colorectal Cancer, By Country/Region,  2015–2022 (USD Million)
Table 29 Liquid Biopsy Market for Prostate Cancer, By Country/Region,  2015–2022 (USD Million)
Table 30 Liquid Biopsy Market for Melanoma, By Country/Region,  2015–2022 (USD Million)
Table 31 Liquid Biopsy Market for Other Cancers, By Country/Region,  2015–2022 (USD Million)
Table 32 Liquid Biopsy Market for Non-Cancer Applications, By Country/Region, 2015–2022 (USD Million)
Table 33 Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 34 Liquid Biopsy Market for Reference Laboratories, By Country/Region,  2015–2022 (USD Million)
Table 35 Liquid Biopsy Market for Hospitals and Physician Laboratories, By Country/ Region, 2015–2022 (USD Million)
Table 36 Liquid Biopsy Market for Academic and Research Centers, By Country/ Region, 2015–2022 (USD Million)
Table 37 Liquid Biopsy Market for Other End Users, By Country/Region,  2015–2022 (USD Million)
Table 38 Liquid Biopsy Market, By Region, 2015–2022 (USD Million)
Table 39 Estimated New Cases of Cancer in 2017, Us
Table 40 North America: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 41 North America: Liquid Biopsy Market, By Product & Service,  2015–2022 (USD Million)
Table 42 North America: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 43 North America: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 44 North America: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 45 North America: Liquid Biopsy Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 46 North America: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 47 US: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 48 US: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 49 US: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 50 US: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 51 US: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 52 US: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 53 Overview of the Breast, Cervical, and Colorectal Cancer Screening Programs Across Canada
Table 54 Canada: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 55 Canada: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 56 Canada: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 57 Canada: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 58 Canada: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Thousands)
Table 59 Canada: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 60 Europe: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 61 Europe: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 62 Europe: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 63 Europe: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 64 Europe: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 65 Europe: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 66 Europe: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 67 Germany: Liquid Biopsy Market, By Product & Service,  2015–2022 (USD Million)
Table 68 Germany: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 69 Germany: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 70 Germany: Liquid Biopsy Market for Cancer Applications, By Cancer Type, 2015–2022 (USD Million)
Table 71 Germany: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 72 Germany: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 73 France: Key Market Indicators
Table 74 France: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 75 France: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 76 France: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 77 France: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 78 France: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 79 France: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 80 UK: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 81 UK: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 82 UK: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 83 UK: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 84 UK: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 85 UK: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 86 RoE: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 87 RoE: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 88 RoE: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 89 RoE: Liquid Biopsy Market for Cancer Applications, By Cancer Type,  2015–2022 (USD Million)
Table 90 RoE: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 91 RoE: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 92 Asia Pacific: Liquid Biopsy Market, By Country, 2015–2022 (USD Million)
Table 93 Asia Pacific: Liquid Biopsy Market, By Product & Service,  2015–2022 (USD Million)
Table 94 Asia Pacific: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 95 Asia Pacific: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 96 Asia Pacific: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 97 Asia Pacific: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 98 Asia Pacific: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 99 Japan: Key Market Indicators
Table 100 Japan: Liquid Biopsy Market, By Product & Service,  2015–2022 (USD Million)
Table 101 Japan: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 102 Japan: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 103 Japan: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 104 Japan: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 105 Japan: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 106 China: Key Market Indicators
Table 107 China: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 108 China: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 109 China: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 110 China: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 111 China: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 112 China: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 113 India: Key Market Indicators:
Table 114 India: Liquid Biopsy Market, By Product & Service,  2015–2022 (USD Million)
Table 115 India: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 116 India: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 117 India: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 118 India: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 119 India: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 120 RoAPAC: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 121 RoAPAC: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 122 RoAPAC: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 123 RoAPAC: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 124 RoAPAC: Liquid Biopsy Market, By Clinical Application,  2015–2022 (USD Million)
Table 125 RoAPAC: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 126 RoW: Liquid Biopsy Market, By Product & Service, 2015–2022 (USD Million)
Table 127 RoW: Liquid Biopsy Circulating Biomarkers Market, By Type,  2015–2022 (USD Million)
Table 128 RoW: Liquid Biopsy Market, By Application, 2015–2022 (USD Million)
Table 129 RoW: Liquid Biopsy Market, By Type of Cancer, 2015–2022 (USD Million)
Table 130 RoW: Liquid Biopsy Market, By Clinical Application, 2015–2022 (USD Million)
Table 131 RoW: Liquid Biopsy Market, By End User, 2015–2022 (USD Million)
Table 132 Liquid Biopsy Market, By Key Player, 2016
Table 133 CHF to USD Conversion Rates (2014-2016)


List of Figures (45 Figures)

Figure 1 Liquid Biopsy: Market Segmentation
Figure 2 Research Design
Figure 3 Market Size Estimation: Bottom-Up Approach
Figure 4 Market Size Estimation: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation,  and Region
Figure 6 Liquid Biopsy Market, By Product and Service, 2017 vs. 2022
Figure 7 Liquid Biopsy Market, By Clinical Application, 2017 vs. 2022
Figure 8 Liquid Biopsy Market, By Application, 2017 vs. 2022
Figure 9 Liquid Biopsy Market, By End User, 2017 vs. 2022
Figure 10 Geographical Snapshot of the Global Liquid Biopsy Market
Figure 11 Increasing Cancer Prevalence—Major Growth Driver for the Liquid Biopsy Market
Figure 12 Therapy Selection Segment to Dominate the Liquid Biopsy Market  in 2017
Figure 13 China to Register the Largest CAGR in the Forecast Period for Liquid Biopsy Market
Figure 14 Asia Pacific to Grow at the Highest CAGR During the Forecast Period
Figure 15 Emerging Markets to Grow at Higher CAGRs From 2017 to 2022
Figure 16 Liquid Biopsy Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Estimated New Cancer Cases and Estimated Deaths in Us (2017)
Figure 18 Cancer Prevalence and Mortality Rate, By Country (2012)
Figure 19 Pubmed Publications—Liquid Biopsy
Figure 20 Estimated New Cancer Cases and Deaths (2016)
Figure 21 North America: Liquid Biopsy Market Snapshot
Figure 22 US: Cancer Statistics
Figure 23 Canada: Cancer Statistics
Figure 24 Europe: Proportion of Deaths Due to Cancer in the Eu (2013)
Figure 25 Europe: Deaths Due to Cancer in the Population Aged 65 and Over (2013)
Figure 26 Germany: Cancer Incidence and Prevalence, 2010 vs. 2015
Figure 27 UK: Estimated Number of People Living With Cancer
Figure 28 RoE: Incidence and Prevalence of Cancer, 2015
Figure 29 Asia Pacific: Liquid Biopsy Market Snapshot
Figure 30 Japan: Cancer Incidence and Prevalence Number, 2010 vs. 2015
Figure 31 China: Cancer Incidence and Prevalence Number, 2010 vs 2015
Figure 32 India: Cancer Incidence and Prevalence Number, 2010 vs 2015
Figure 33 Rest of Asia Pacific: Number of Cancer Cases, 2015
Figure 34 Liquid Biopsy Market (Global),  Competitive Leadership Mapping 2017
Figure 35 Biocept, Inc.: Company Snapshot (2016)
Figure 36 Qiagen N.V.: Company Snapshot (2016)
Figure 37 Roche Diagnostics: Company Snapshot (2016)
Figure 38 Bio-Rad Laboratories, Inc.: Company Snapshot (2016)
Figure 39 Myriad Genetics, Inc: Company Snapshot (2016)
Figure 40 Menarini Group: Company Snapshot (2016)
Figure 41 Trovagene Inc.: Company Snapshot (2016)
Figure 42 Mdxhealth: Company Snapshot (2016)
Figure 43 Genomic Health, Inc.: Company Snapshot (2016)
Figure 44 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 45 Illumina Inc.: Company Snapshot (2016)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 4456
Published ON
Oct, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Liquid Biopsy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home